Reports Q3 revenue $16.9M, consensus $18.15M. "CytomX’s progress in the third quarter highlights the potential of our pipeline as well as the breadth and versatility of the Probody(R) platform. CX-2051 and CX-801 are wholly owned, next generation therapeutic candidates that build on our deep experience with conditional activation," said Sean McCarthy, D.Phil., chief executive officer and chairman at CytomX Therapeutics. "We also continued to make progress in our collaborator programs, including CX-904, our first T-cell engager in the clinic, and BMS-986249, for which Bristol Myers Squibb presented updated Phase 1 safety and efficacy data at ESMO 2022."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CTMX:
- CytomX Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
- CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b (CX-801) at the SITC 2022 Annual Meeting
- CytomX Therapeutics to Present at Upcoming November Investor Conferences
- CytomX Therapeutics Announces Phase 1 Data Update for anti-CTLA-4 Probody® Therapeutic BMS-986249
